Stockscreener 앱 받기
14.52
6.38%
-0.99
시장 영업 전:
13.61
-0.91
-6.27%
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks
Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia
Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com India
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - BioSpace
KalVista price target raised to $27 from $19 at Citizens JMP - MSN
KalVista Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins - Investing.com Nigeria
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - TradingView
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended April 30, 2025 - MarketScreener
Kalvista Pharmaceuticals Inc reports results for the quarter ended April 30Earnings Summary - TradingView
Kalvista Pharmaceuticals IncFDA approves Kalvista's Ekterly for hereditary angioedema - MarketScreener
KalVista price target raised to $37 from $22 at BofA - Yahoo Finance
US High Growth Tech Stocks Leading The Market - Yahoo Finance
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More - iHeart
KalVista Pharmaceuticals executives sell 63,129 shares at $15.69/share on 2025-07-09. - AInvest
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning (KALV) - Seeking Alpha
Dri Healthcare comments on FDA approval and our increased investment in Kalvista Pharmaceuticals' Ekterly - MarketScreener
DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals' Ekterly® (sebetralstat) - Yahoo Finance
Kalvista stock price target raised to $27 from $19 at JMP on Ekterly pricing - Investing.com Nigeria
KalVista secures FDA approval for Ekterly to treat HAE attacks - World Pharmaceutical Frontiers
Oral HAE Breakthrough: KalVista's EKTERLY® and Orsini Partnership Signal a New Era for Patients and Investors - AInvest
FDA approves KalVista’s oral HAE treatment Ekterly By Investing.com - Investing.com Nigeria
KalVista’s Delayed FDA Approval In HAE Comes Through - insights.citeline.com
Kalvista stock rises as Leerink raises price target on FDA approval - Investing.com Nigeria
FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema - Managed Healthcare Executive
KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease - MedCity News
FDA approves first-of-a-kind oral therapy for rare disease - MarketScreener
FDA Clears First Oral HAE Treatment S&P 500 Focus Turns to KalVista - Kalkine Media
KalVista stock price target raised to $37 from $22 at BofA on Ekterly approval - Investing.com
FDA OKs sebetralstat, now Ekterly, as oral on-demand HAE therapy - Angioedema News
After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder - BioPharma Dive
Transcript : KalVista Pharmaceuticals, Inc.Special Call - MarketScreener
Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat) - PR Newswire
KalVista's breakthrough drug wins FDA approval after delay - The Business Journals
Kalvista stock jumps as Stifel reiterates Buy rating on Ekterly approval - Investing.com Nigeria
US FDA approves KalVista's oral swelling disorder drug, shares rise - Reuters
Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld MedTech
FDA approves KalVista’s Ekterly for hereditary angioedema - Yahoo Finance
KalVista Pharmaceuticals rises after FDA nod for Ekterly (KALV) - Seeking Alpha
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday - Benzinga
KalVista Shares Surge as FDA Approves New Drug After Delay - Bloomberg
KalVista Pharmaceuticals Gains FDA Approval for EKTERLY® - TipRanks
KalVista wins FDA greenlight for Ekterly - The Pharma Letter
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill - BioSpace
US FDA approves KalVista Pharma's swelling disorder drug, shares rise - MarketScreener
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated - Stocktwits
KalVista bags FDA approval for delayed oral HAE drug - pharmaphorum
KalVista's Ekterly: A Breakthrough in Rare Disease Therapeutics and a Buy Opportunity - AInvest
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease - 富途牛牛
Tesla, Constellation Brands, KalVista Pharma - TradingView
KalVista stock soars after FDA approves first oral HAE treatment - Investing.com
FDA approves KalVista’s oral HAE treatment Ekterly - Investing.com
KalVista Pharmaceuticals Soars 26.88% on FDA Approval, Investor Buying - AInvest
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - New Castle News
Pendopharm, Kalvista to bring sebetralstat for HAE to Canada - Angioedema News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Joplin Globe
Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada - Barchart.com
KalVista (KALV) Partners with Pendopharm for Sebetralstat in Canada | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada - Lelezard
KalVista (KALV) Awaits FDA Decision Amid Unexpected News | KALV Stock News - GuruFocus
Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say - Endpoints News
FDA delays Kalvista’s sebetralstat decision due to resource constraints By Investing.com - Investing.com Nigeria
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’ - BioPharma Dive
FDA delays Kalvista’s sebetralstat decision due to resource constraints - Investing.com
2.10%
1.57%
자본화:
|
볼륨(24시간):